Indivior Pharmaceuticals, Inc. INDV
Set alert
36.28 USD +0.91 +2.57%
At close · Nov 2
36.30 +0.02 +0.06%
After hours · Nov 2, 4:00 PM ET
35.32 Day range 37.01
27.68 52-week range 42.81
- YTD
- +1.11%
- 1 year
- +23.53%
- Open
- 35.43
- Prev close
- 35.37
- Mkt cap
- 4.28B
- Vol
- 4.87M
- Avg vol
- 2.42M
- EPS
- 3.57
- P/E
- 10.16
- Div yield
- 0.00%
More statistics
- Low
- 35.32
- High
- 37.01
- Forward P/E
- 8.05
- Beta
- 1.13
- Short ratio
- 3.89
- Inst. own
- 104.85%
- Dividend
- 0.00
- Ex-div date
- Nov 2, 2026
- Earnings
- Feb 25, 2027
- 50-d avg
- 35.20
- 200-d avg
- 35.66
- 1y target
- 49.50
1M chart
Events in this range
- Oct 28, 2026Rating: Barclays · Overweight → Overweight
- Oct 29, 2026Earnings: 1.32; estimate 1.06; surprise 24.53%
- Oct 30, 2026Dividend: 8.13
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 49.50 +36.4% upside
Now 36.28
- Target (low)
- 45.00
- Target (mean)
- 49.50
- Target (high)
- 53.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.22 | 1.22 – 1.22 | 0.82 | +48.8% | 337.90M | -5.6% | 1 |
| Next quarter | 0.9395 | 0.859 – 1.02 | 0.96 | -2.1% | 328.00M | +3.5% | 2 |
| Current year | 4.42 | 4.36 – 4.47 | 2.50 | +76.6% | 1.33B | +7.5% | 2 |
| Next year | 4.51 | 3.89 – 4.89 | 4.42 | +2.1% | 1.40B | +5.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 18, 2026 | Barclays | Initiated | — | Overweight |
| Jan 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 31, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 30, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 27, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 6, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 30, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 6, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 25, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 11, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Oct 11, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 13, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 23, 2024 | Piper Sandler | Initiated | — | Overweight |
| Jul 10, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Apr 3, 2024 | Craig-Hallum | Initiated | — | Buy |